Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: RASSF2

Gene summary for RASSF2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

RASSF2

Gene ID

9770

Gene nameRas association domain family member 2
Gene AliasCENP-34
Cytomap20p13
Gene Typeprotein-coding
GO ID

GO:0000165

UniProtAcc

P50749


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
9770RASSF2ATC13HumanThyroidATC9.49e-356.81e-010.34
9770RASSF2ATC5HumanThyroidATC2.44e-367.50e-010.34
Page: 1 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:003164734ThyroidATCregulation of protein stability177/6293298/187234.08e-206.46e-18177
GO:001056334ThyroidATCnegative regulation of phosphorus metabolic process234/6293442/187232.30e-172.31e-15234
GO:004593634ThyroidATCnegative regulation of phosphate metabolic process233/6293441/187233.68e-173.47e-15233
GO:000193333ThyroidATCnegative regulation of protein phosphorylation186/6293342/187231.43e-151.08e-13186
GO:005082134ThyroidATCprotein stabilization117/6293191/187233.98e-152.71e-13117
GO:004232634ThyroidATCnegative regulation of phosphorylation203/6293385/187235.30e-153.53e-13203
GO:000150332ThyroidATCossification206/6293408/187239.23e-133.95e-11206
GO:000164932ThyroidATCosteoblast differentiation122/6293229/187236.04e-101.60e-08122
GO:004586026ThyroidATCpositive regulation of protein kinase activity185/6293386/187233.00e-097.02e-08185
GO:0038127111ThyroidATCERBB signaling pathway71/6293121/187231.31e-082.69e-0771
GO:001810519ThyroidATCpeptidyl-serine phosphorylation153/6293315/187232.28e-084.42e-07153
GO:0048872210ThyroidATChomeostasis of number of cells135/6293272/187232.92e-085.50e-07135
GO:001820917ThyroidATCpeptidyl-serine modification161/6293338/187235.23e-089.44e-07161
GO:003367427ThyroidATCpositive regulation of kinase activity212/6293467/187235.89e-081.05e-06212
GO:0007173111ThyroidATCepidermal growth factor receptor signaling pathway63/6293108/187231.15e-071.92e-0663
GO:004677717ThyroidATCprotein autophosphorylation114/6293227/187231.54e-072.49e-06114
GO:003109826ThyroidATCstress-activated protein kinase signaling cascade120/6293247/187237.06e-079.46e-06120
GO:005140326ThyroidATCstress-activated MAPK cascade115/6293239/187232.17e-062.58e-05115
GO:003009933ThyroidATCmyeloid cell differentiation170/6293381/187234.26e-064.68e-05170
GO:004566721ThyroidATCregulation of osteoblast differentiation66/6293132/187237.03e-055.36e-0466
Page: 1 2 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
RASSF2SNVMissense_Mutationnovelc.926N>Ap.Arg309Glnp.R309QP50749protein_codingtolerated(0.05)benign(0.01)TCGA-3C-AALI-01Breastbreast invasive carcinomaFemale<65I/IIUnspecificPoly EComplete Response
RASSF2SNVMissense_Mutationrs746569074c.497N>Ap.Arg166Hisp.R166HP50749protein_codingdeleterious(0.01)probably_damaging(0.97)TCGA-E2-A14S-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapycytoxanSD
RASSF2insertionNonsense_Mutationnovelc.538_539insGGGACGCCGTCTAACAAGCCTGCAGGGGATTTGGATp.Thr180delinsArgAspAlaValTerGlnAlaCysArgGlyPheGlySerp.T180delinsRDAV*QACRGFGSP50749protein_codingTCGA-A7-A0CJ-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycytoxanSD
RASSF2deletionFrame_Shift_Delc.70_74delNNNNNp.Leu24AlafsTer10p.L24Afs*10P50749protein_codingTCGA-AR-A0TW-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapydoxorubicinPD
RASSF2SNVMissense_Mutationc.952G>Cp.Glu318Glnp.E318QP50749protein_codingtolerated(0.63)benign(0.198)TCGA-C5-A1MK-01Cervixcervical & endocervical cancerFemale>=65III/IVChemotherapycarboplatinPD
RASSF2SNVMissense_Mutationc.263N>Gp.Ser88Cysp.S88CP50749protein_codingdeleterious(0)probably_damaging(0.994)TCGA-IR-A3LK-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycisplatinPD
RASSF2SNVMissense_Mutationrs369276882c.581G>Ap.Arg194Hisp.R194HP50749protein_codingdeleterious(0)probably_damaging(0.999)TCGA-UC-A7PF-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
RASSF2SNVMissense_Mutationrs192780679c.908N>Ap.Arg303Hisp.R303HP50749protein_codingtolerated(0.23)benign(0.138)TCGA-AA-3663-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
RASSF2SNVMissense_Mutationc.398N>Cp.Leu133Prop.L133PP50749protein_codingtolerated(0.32)benign(0.024)TCGA-AA-3821-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
RASSF2SNVMissense_Mutationc.227N>Ap.Arg76Hisp.R76HP50749protein_codingdeleterious(0.02)possibly_damaging(0.87)TCGA-AA-3949-01Colorectumcolon adenocarcinomaFemale>=65III/IVUnknownUnknownSD
Page: 1 2 3 4 5 6 7 8 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1